Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 3 6Phase 2 5Phase 4 2Phase 1/2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Vomiting 1Nausea 1Multiple Myeloma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × fosaprepitant × Clear all
NCT02780609 2022-11-04

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
22 enrolled 16 charts
Plasma cell

Multiple Myeloma

NCT01031953 2017-05-09

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

OHSU Knight Cancer Institute

Phase 1/2 Terminated
34 enrolled 12 charts

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡